Scaling AI Across the Biopharma Enterprise

Session details:

While early AI discussions centered on discovery acceleration and regulatory credibility, the next challenge is organizational transformation. This panel examines how biotech and pharma leaders are embedding AI across the enterprise from R&D and CMC to clinical operations, business development, and corporate strategy. As communities converge, AI is no longer a tool but an operating layer shaping how companies allocate capital, form partnerships, and compete globally.

Key Discussion Points

• Transitioning from isolated AI pilots to integrated enterprise platforms
• Organizational design: talent, governance, and cross-functional alignment
• AI in deal-making, asset prioritization, and portfolio strategy
• Data infrastructure as a competitive moat
• Expectations and capital allocation in AI-driven companies